An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.
Clinical trial NCT06985316 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06985316
- Sponsor
- Liu Huang
- Status
- NOT_YET_RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-19
- Primary completion
- 2028-04-27
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.